WEST CHESTER, Pa. & ISTANBOEL–(BUSINESS WIRE)– Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) heeft vandaag hun overeenkomst aangekondigd met Molecular Targeting Technologies, Inc. (MTTI), een biotechbedrijf in de klinische fase dat zich richt op het ontwikkelen van innovatieve therapieën voor zeldzame kankers, voor de levering van de medische radio-isotoop no-carrier- added ¹⁷⁷Lu (n.c.a. ¹⁷⁷Lu).

Eczacıbaşı-Monrol betrad de theranostische markt in 2019 als een van de weinige producenten van lutetium-177 wereldwijd en heeft sindsdien een ononderbroken levering van dit kritieke product aan patiënten in veel landen geleverd. In lijn met haar missie om de kwaliteit van leven van kankerpatiënten wereldwijd te verbeteren, gaat het bedrijf strategische partnerschappen aan met internationale farmaceutische bedrijven en bouwt het een nieuwe productiefaciliteit die voldoet aan de FDA 21 CFR Part 211 kwaliteitsnormen met een jaarlijkse capaciteit van 60 duizend doses. Dankzij de ligging dicht bij het transportknooppunt van Istanboel, zal de nieuwe faciliteit profiteren van een wereldwijd logistiek netwerk en overeenkomsten met vrachtdiensten naar 320 bestemmingen wereldwijd.

 MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.

WEST CHESTER, Pa. & ISTANBUL–(BUSINESS WIRE)– Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added ¹⁷⁷Lu (n.c.a. ¹⁷⁷Lu).

Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul’s transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.

Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.¹⁷⁷Lu contributes to the company’s mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, “To support our growth in this field, we’re establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world.”

Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, ” We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset ¹⁷⁷Lu-EBTATE and other EB platform technologies. We are excited to start

this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.¹⁷⁷Lu.”

About Molecular Targeting Technologies, Inc. (MTTI)

Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com; www.evathera.com

About Eczacıbaşı-Monrol

Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.

Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006032/en/

Contacts

MTTI
Mr. Chris Pak

President & CEO

Email:cpak@mtarget.com

Eczacıbaşı Monrol
Mr. Aydın Küçük

General Manager

Email: aydin.kucuk@monrol.com